RO5166017

RO5166017 is a drug that acts as a potent and selective agonist for the neuropeptide receptor NPSR1. This drug was developed by Hoffmann-La Roche, a Swiss multinational healthcare company.

Pharmacology

RO5166017 is a synthetic compound that has been shown to have high affinity and selectivity for the NPSR1. It is an agonist, meaning it binds to the receptor and activates it, leading to a biological response. In the case of RO5166017, this response is typically an increase in wakefulness and anxiety-like behavior.

Clinical Significance

The NPSR1 is a receptor that is involved in the regulation of sleep and anxiety. Therefore, drugs that can modulate the activity of this receptor, such as RO5166017, have potential therapeutic applications in the treatment of sleep disorders and anxiety disorders. However, as of now, RO5166017 is primarily used in scientific research to help understand the role of the NPSR1 in the body.

Research

Research on RO5166017 has provided valuable insights into the function of the NPSR1. For example, studies have shown that activation of the NPSR1 by RO5166017 can increase wakefulness and produce anxiety-like behavior in animals. This suggests that the NPSR1 may play a role in regulating sleep and anxiety.

See Also

• Neuropeptide S
• Neuropeptide S receptor 1
• Hoffmann-La Roche

References

‎